JP2012528240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012528240A5 JP2012528240A5 JP2012513256A JP2012513256A JP2012528240A5 JP 2012528240 A5 JP2012528240 A5 JP 2012528240A5 JP 2012513256 A JP2012513256 A JP 2012513256A JP 2012513256 A JP2012513256 A JP 2012513256A JP 2012528240 A5 JP2012528240 A5 JP 2012528240A5
- Authority
- JP
- Japan
- Prior art keywords
- phf
- conjugate
- gly
- cpt
- conjugate according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940127093 camptothecin Drugs 0.000 claims description 46
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 25
- 125000005647 linker group Chemical group 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 125000001142 dicarboxylic acid group Chemical group 0.000 claims description 18
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 16
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 14
- 229930182556 Polyacetal Natural products 0.000 claims description 13
- 229920001855 polyketal Polymers 0.000 claims description 13
- 229920006324 polyoxymethylene Polymers 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 210000000214 mouth Anatomy 0.000 claims description 8
- 210000003739 neck Anatomy 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 4
- 210000000436 anus Anatomy 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000003238 esophagus Anatomy 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 claims description 4
- 210000003128 head Anatomy 0.000 claims description 4
- 201000011066 hemangioma Diseases 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000000867 larynx Anatomy 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 150000002894 organic compounds Chemical class 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 210000003800 pharynx Anatomy 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 210000000664 rectum Anatomy 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 210000001550 testis Anatomy 0.000 claims description 4
- 210000003932 urinary bladder Anatomy 0.000 claims description 4
- 210000004291 uterus Anatomy 0.000 claims description 4
- IICQZTQZQSBHBY-HWKANZROSA-N (e)-non-2-ene Chemical compound CCCCCC\C=C\C IICQZTQZQSBHBY-HWKANZROSA-N 0.000 claims description 3
- IICQZTQZQSBHBY-UHFFFAOYSA-N 2t-nonene Natural products CCCCCCC=CC IICQZTQZQSBHBY-UHFFFAOYSA-N 0.000 claims description 3
- CEVCTNCUIVEQOY-UHFFFAOYSA-N Fumagillol Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(O)CCC21CO2 CEVCTNCUIVEQOY-UHFFFAOYSA-N 0.000 claims description 2
- 150000001414 amino alcohols Chemical class 0.000 claims description 2
- 125000005365 aminothiol group Chemical class 0.000 claims description 2
- 230000001588 bifunctional effect Effects 0.000 claims description 2
- 150000004985 diamines Chemical class 0.000 claims description 2
- CEVCTNCUIVEQOY-STXHBLNNSA-N fumagillol Chemical compound C([C@@H](O)[C@H](C1[C@]2(C)[C@H](O2)CC=C(C)C)OC)C[C@@]21CO2 CEVCTNCUIVEQOY-STXHBLNNSA-N 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 150000003335 secondary amines Chemical class 0.000 claims description 2
- 150000003512 tertiary amines Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 229920001307 poly(hydroxymethylethylene hydroxymethyl formal) Polymers 0.000 claims 5
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- -1 2-nonen-2-yl Chemical group 0.000 claims 1
- 229930190064 illudin Natural products 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 2
- 239000000872 buffer Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18192609P | 2009-05-28 | 2009-05-28 | |
| US61/181,926 | 2009-05-28 | ||
| PCT/US2010/036413 WO2010138719A1 (en) | 2009-05-28 | 2010-05-27 | Polyal drug conjugates comprising variable rate-releasing linkers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012528240A JP2012528240A (ja) | 2012-11-12 |
| JP2012528240A5 true JP2012528240A5 (OSRAM) | 2013-05-30 |
Family
ID=43220947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513256A Pending JP2012528240A (ja) | 2009-05-28 | 2010-05-27 | 可変速度放出リンカーを含むポリアル−薬物コンジュゲート |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8524214B2 (OSRAM) |
| EP (1) | EP2435053B1 (OSRAM) |
| JP (1) | JP2012528240A (OSRAM) |
| KR (1) | KR20120057588A (OSRAM) |
| CN (1) | CN102448469A (OSRAM) |
| AR (1) | AR078510A1 (OSRAM) |
| AU (1) | AU2010254013A1 (OSRAM) |
| CA (1) | CA2762877A1 (OSRAM) |
| IL (1) | IL216325A0 (OSRAM) |
| TW (1) | TW201102089A (OSRAM) |
| WO (1) | WO2010138719A1 (OSRAM) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2217283A2 (en) * | 2007-11-28 | 2010-08-18 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
| CA2794307A1 (en) * | 2010-03-26 | 2011-09-29 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| WO2012092339A2 (en) * | 2010-12-28 | 2012-07-05 | The Children's Hospital Of Philadelphia | The design of hydrolytically releasable prodrugs for sustained release nanoparticle formulations |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2717916B1 (en) * | 2011-06-10 | 2017-03-08 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| AU2012332588B2 (en) | 2011-11-01 | 2017-09-07 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| EP2794582A1 (en) * | 2011-12-23 | 2014-10-29 | Mersana Therapeutics, Inc. | Pharmaceutical formulations for fumagillin derivative-phf conjugates |
| US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| AU2013359506B2 (en) * | 2012-12-10 | 2018-05-24 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2931316B1 (en) | 2012-12-12 | 2019-02-20 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
| KR102178606B1 (ko) | 2013-03-15 | 2020-11-13 | 자임워크스 인코포레이티드 | 세포독성 및 유사분열-억제 화합물, 및 이를 사용하는 방법 |
| SG11201602258WA (en) | 2013-10-04 | 2016-04-28 | Prolynx Llc | Slow-release conjugates of sn-38 |
| WO2015054669A1 (en) | 2013-10-11 | 2015-04-16 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
| EA032231B1 (ru) | 2013-10-11 | 2019-04-30 | Мерсана Терапьютикс, Инк. | Конъюгаты белок-полимер-лекарственное средство |
| RU2729194C2 (ru) | 2013-12-27 | 2020-08-05 | Займворкс Инк. | Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов |
| RU2723651C2 (ru) | 2014-09-17 | 2020-06-17 | Займворкс Инк. | Цитотоксические и антимитотические соединения и способы их применения |
| US10011657B2 (en) | 2014-10-31 | 2018-07-03 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
| SI3218005T1 (sl) | 2014-11-12 | 2023-06-30 | Seagen Inc. | Z glikanom delujoče spojine, in postopki uporabe |
| WO2016094505A1 (en) | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Antibody drug conjugates with cell permeable bcl-xl inhibitors |
| MX2017007629A (es) | 2014-12-09 | 2018-05-17 | Abbvie Inc | Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen. |
| EP3371223B1 (en) | 2015-11-03 | 2021-03-10 | Merck Patent GmbH | Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof |
| CA3002097A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| ES2810755T3 (es) | 2015-11-30 | 2021-03-09 | Abbvie Inc | Conjugados fármaco-anticuerpo anti-lrrc15 humano y métodos para su uso |
| CA3006610A1 (en) | 2015-11-30 | 2017-06-08 | Abbvie Inc. | Anti-hulrrc15 antibody drug conjugates and methods for their use |
| EP3432925A4 (en) | 2016-03-22 | 2019-11-06 | Bionomics Limited | ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY |
| MX2018014175A (es) | 2016-05-17 | 2020-02-07 | Abbvie Biotherapeutics Inc | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. |
| CA3026434A1 (en) * | 2016-06-03 | 2017-12-07 | Novacyte, Inc. | Polymer linkers and their uses |
| BR112018075645A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | conjugados de anticorpo fármaco anti-egfr |
| JP2019521114A (ja) | 2016-06-08 | 2019-07-25 | アッヴィ・インコーポレイテッド | 抗ｅｇｆｒ抗体薬物コンジュゲート |
| RU2018147224A (ru) | 2016-06-08 | 2020-07-14 | Эббви Инк. | Конъюгаты антитела к egfr и лекарственного средства |
| IL300274A (en) | 2016-06-08 | 2023-04-01 | Abbvie Inc | Antibodies against B7–H3 and conjugates of drug and antibody |
| EP3468598A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| WO2017214462A2 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| JP2019522643A (ja) | 2016-06-08 | 2019-08-15 | アッヴィ・インコーポレイテッド | 抗ｃｄ９８抗体及び抗体薬物コンジュゲート |
| BR112018075649A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo |
| EP3468993A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| WO2018004338A1 (en) | 2016-06-27 | 2018-01-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| HRP20210744T1 (hr) | 2016-09-14 | 2021-06-25 | Merck Patent Gmbh | Anti-c-met protutijela i njihovi konjugati protutijelo lijek za učinkovitu inhibiciju tumora |
| CA3041254A1 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
| EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| BR112019013107A2 (pt) | 2016-12-22 | 2019-12-17 | Univ Degli Studi Magna Graecia Catanzaro | anticorpos, molécula de ligação, receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, linfócito, ácido nucleico, célula de hibridoma, método para a produção do anticorpo monoclonal e usos |
| EP3589319A4 (en) | 2017-03-03 | 2021-07-14 | Seagen Inc. | COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE |
| JP7320458B2 (ja) | 2017-06-22 | 2023-08-03 | メルサナ セラピューティクス インコーポレイテッド | 薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法 |
| US11730836B2 (en) | 2018-01-12 | 2023-08-22 | Prolynx Llc | Synergistic cancer treatment |
| ES2975330T3 (es) | 2018-05-04 | 2024-07-04 | Tagworks Pharmaceuticals B V | Compuestos que comprenden un enlazador para aumentar la estabilidad del trans-cicloocteno |
| EP3787691A1 (en) | 2018-05-04 | 2021-03-10 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
| JP7398396B2 (ja) | 2018-06-01 | 2023-12-14 | ノバルティス アーゲー | Ｂｃｍａに対する結合分子及びその使用 |
| WO2019234136A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
| EP3873534A1 (en) | 2018-10-29 | 2021-09-08 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
| EP3972998A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Cd19 binding molecules and uses thereof |
| EP3972993A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Variant cd58 domains and uses thereof |
| CA3143925A1 (en) | 2019-06-17 | 2020-12-24 | Tagworks Pharmaceuticals B.V. | Compounds for fast and efficient click release |
| IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
| AU2020327000A1 (en) | 2019-08-08 | 2022-03-31 | Regeneron Pharmaceuticals, Inc. | Novel antigen binding molecule formats |
| AU2020379735A1 (en) | 2019-11-05 | 2022-05-26 | Regeneron Pharmaceuticals, Inc. | N-terminal SCFV multispecific binding molecules |
| EP4087657A1 (en) | 2020-01-08 | 2022-11-16 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| WO2021178896A1 (en) | 2020-03-06 | 2021-09-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| US20230128499A1 (en) | 2020-03-27 | 2023-04-27 | Novartis Ag | Bispecific combination therapy for treating proliferative diseases and autoimmune diseases |
| US11028132B1 (en) | 2020-04-07 | 2021-06-08 | Yitzhak Rosen | Half-life optimized linker composition |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| US20250326855A1 (en) | 2021-03-05 | 2025-10-23 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| KR20240107093A (ko) | 2021-08-05 | 2024-07-08 | 고 테라퓨틱스, 인크. | 항-글리코-muc4 항체 및 그의 용도 |
| AU2022339819A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
| TW202328188A (zh) | 2021-09-03 | 2023-07-16 | 美商Ｇｏ治療公司 | 抗醣化-cmet抗體及其用途 |
| US20250327057A1 (en) | 2021-09-06 | 2025-10-23 | Veraxa Biotech Gmbh | Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes |
| CA3238627A1 (en) | 2021-11-25 | 2023-06-01 | Christine Kohler | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
| DK4186529T3 (da) | 2021-11-25 | 2025-08-25 | Veraxa Biotech Gmbh | Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse |
| US20250135011A1 (en) | 2021-12-08 | 2025-05-01 | European Molecular Biology Laboratory | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
| EP4314031B1 (en) | 2022-02-15 | 2024-03-13 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
| KR20250049569A (ko) | 2022-07-15 | 2025-04-11 | 페온 테라퓨틱스 리미티드 | 항체-약물 접합체 |
| WO2024080872A1 (en) | 2022-10-12 | 2024-04-18 | Tagworks Pharmaceuticals B.V. | Strained bicyclononenes |
| EP4649092A1 (en) | 2023-01-13 | 2025-11-19 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| CN120569216A (zh) | 2023-01-20 | 2025-08-29 | 巴斯夫欧洲公司 | 稳定型生物聚合物组合物、其制造和用途 |
| AU2024237490A1 (en) | 2023-03-10 | 2025-09-25 | Tagworks Pharmaceuticals B.V. | Trans-cyclooctene with improved t-linker |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| WO2025021929A1 (en) | 2023-07-27 | 2025-01-30 | Veraxa Biotech Gmbh | Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same |
| WO2025056807A1 (en) | 2023-09-15 | 2025-03-20 | Basf Se | Stabilized biopolymer composition, their manufacture and use |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025174248A1 (en) | 2024-02-16 | 2025-08-21 | Tagworks Pharmaceuticals B.V. | Trans-cyclooctenes with "or gate" release |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| US5811510A (en) | 1995-04-14 | 1998-09-22 | General Hospital Corporation | Biodegradable polyacetal polymers and methods for their formation and use |
| WO1998056372A1 (en) | 1997-06-09 | 1998-12-17 | Massachusetts Institute Of Technology | TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF |
| US20020103136A1 (en) | 1998-03-05 | 2002-08-01 | Dong-Mei Feng | Conjugates useful in the treatment of prostate cancer |
| WO1999061432A1 (en) | 1998-05-12 | 1999-12-02 | Biochem Pharma Inc. | Fumagillin analogs and their use as angiogenesis inhibitors |
| US6603812B1 (en) | 1998-08-17 | 2003-08-05 | Linear Technology Corporation | Hardware implementation of a decimating finite impulse response filter |
| US7790150B2 (en) * | 2003-09-05 | 2010-09-07 | The General Hospital Corporation | Dual phase drug release system |
| JP2008534747A (ja) * | 2005-03-31 | 2008-08-28 | エーピー ファーマ， インコーポレイテッド | Ｐｅｇ−ポリアセタールグラフトコポリマーおよびｐｅｇ−ポリアセタール−ｐｏｅグラフトコポリマーならびに医薬組成物 |
| US20070019008A1 (en) | 2005-07-22 | 2007-01-25 | Xerox Corporation | Systems, methods, and programs for increasing print quality |
| EP2217283A2 (en) * | 2007-11-28 | 2010-08-18 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
| US20110117009A1 (en) * | 2008-03-31 | 2011-05-19 | Freie Universität Berlin | Drug conjugates with polyglycerols |
-
2010
- 2010-05-27 CA CA2762877A patent/CA2762877A1/en not_active Abandoned
- 2010-05-27 WO PCT/US2010/036413 patent/WO2010138719A1/en not_active Ceased
- 2010-05-27 KR KR1020117031373A patent/KR20120057588A/ko not_active Withdrawn
- 2010-05-27 CN CN2010800236442A patent/CN102448469A/zh active Pending
- 2010-05-27 US US12/789,047 patent/US8524214B2/en not_active Expired - Fee Related
- 2010-05-27 JP JP2012513256A patent/JP2012528240A/ja active Pending
- 2010-05-27 AU AU2010254013A patent/AU2010254013A1/en not_active Abandoned
- 2010-05-27 EP EP10781215.8A patent/EP2435053B1/en not_active Not-in-force
- 2010-05-28 AR ARP100101862A patent/AR078510A1/es not_active Application Discontinuation
- 2010-05-28 TW TW099117180A patent/TW201102089A/zh unknown
-
2011
- 2011-11-13 IL IL216325A patent/IL216325A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012528240A5 (OSRAM) | ||
| JP2012528240A (ja) | 可変速度放出リンカーを含むポリアル−薬物コンジュゲート | |
| JP2014523412A5 (OSRAM) | ||
| JP2014528466A5 (OSRAM) | ||
| JP2019512478A5 (OSRAM) | ||
| JP2010521485A5 (OSRAM) | ||
| CN108601952B (zh) | 雷公藤内酯的葡萄糖缀合物、类似物及其用途 | |
| JP2014534200A5 (OSRAM) | ||
| JP2018507197A5 (OSRAM) | ||
| JP2017504606A5 (OSRAM) | ||
| JP2016534990A5 (OSRAM) | ||
| JP2010509375A5 (OSRAM) | ||
| JP2012512898A5 (OSRAM) | ||
| JP2017503011A5 (OSRAM) | ||
| WO2016050210A1 (zh) | 一种多官能化聚乙二醇衍生物及其制备方法 | |
| JP2014515406A5 (OSRAM) | ||
| JP2016519062A5 (OSRAM) | ||
| JP2013540114A5 (OSRAM) | ||
| JP2018058822A5 (OSRAM) | ||
| JP2013538213A5 (OSRAM) | ||
| JP2019178158A5 (OSRAM) | ||
| JP2012513982A5 (OSRAM) | ||
| TWI439463B (zh) | 青蒿素之二聚衍生物及其在抗癌治療之應用 | |
| JP7353378B2 (ja) | Ｃｄ４４標的化マルチアームコンジュゲート | |
| RU2013152687A (ru) | Мультимер непептидильный полимер-инсулин и способ его получения |